DJIA 16,154.56 -220.20 -1.34%
NASDAQ 4,698.39 -35.11 -0.74%
S&P 500 1,925.62 -25.51 -1.31%
market minute promo

Galena Biopharma, Inc. (NASDAQ: GALE)

1.58 -0.04 (-2.47%)

Quote as of

company name or ticker

Recent Quotes

GALE $1.58 -2.47%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.59
Previous Close $1.62
Daily Range $1.56 - $1.59
52-Week Range $1.10 - $2.50
Market Cap $255.5M
P/E Ratio -5.40
Dividend (Yield) $0.00 (0.0%)
Volume 276,600
Average Daily Volume 1,609,689
Current FY EPS -$0.33




Drug Makers

Galena Biopharma, Inc. (GALE) Description

Galena Biopharma Inc is a biotechnology company focused on discovering developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. Website:

News & Commentary

5 Things Galena Biopharma Wants You to Know

Galena may have delivered the dreaded double miss in the second quarter, but there's much more to this biotech company than meets the eye.

Why Galena Biopharma Jumped 10% Today

Independent monitors are reducing cardiac monitoring in a key Galena Biopharma phase 3 trials.

Ocata Therapeutics: Insider Enrichment, Failed Science, Long History Of Fraud Ties, 77% Downside

Galena Biopharma Comes Up Short in Q2 and Investors Pounce

Galena's earnings results miss the mark once again, but does the promise of its pipeline make this stock a buy?

Galena Biopharma's (GALE) CEO Mark Schwartz on Q2 2015 Results - Earnings Call Transcript

Galena Biopharma Launches Zuplenz Oral Soluble Film

Biotech Weekly: 7 Stock-Specific Reasons Why You Shouldn't Buy That Speculative Biotech

Small Cap Stocks to Watch in Biotech

Small cap stocks can be some of the most intriguing buys for investors. Here are three from the biotech sector that you may want to add to your watchlist.

Biotech Stocks: 2 to Avoid, 1 to Buy

Arrowhead Research Corp. and Galena Biopharma are two speculative biotech stocks that investors may want to avoid, while top dog Celgene Corp. still looks like a great pick up. Here's why.

Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hema

Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress

See More GALE News...

GALE's Top Competitors

GALE $1.58 (-2.47%)
Current stock: GALE
AMGN $147.40 (-1.23%)
Current stock: AMGN
GILD $102.61 (0.69%)
Current stock: GILD
BIIB $299.16 (-0.82%)
Current stock: BIIB